Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CPT1A | P50416 | 12/20 | 0.53 |
| ▸ | RORC | P51449 | 4/20 | 0.47 |
| ▸ | CPT2 | P23786 | 8/20 | 0.46 |
| ▸ | CPT1B | Q92523 | 9/20 | 0.41 |
| ▸ | HTR6 | P50406 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2001536 | 0.90 | RORC (0.58) | CPT1ARORCCPT2CPT1BHTR6 | |
| SCHEMBL2005083 | 0.89 | CPT1A (0.59) | CPT1ARORCCPT2CPT1BHTR6 | |
| SCHEMBL2007284 | 0.86 | CPT1A (0.52) | CPT1ARORCCPT2HTR6CYP2C9 | |
| SCHEMBL2005185 | 0.86 | CPT1A (0.51) | CPT1ARORCCPT2CPT1BCYP2C9 | |
| SCHEMBL2002412 | 0.85 | RORC (0.57) | CPT1ARORCCPT2CPT1B | |
| SCHEMBL2006485 | 0.84 | CPT1A (0.53) | CPT1ARORCCPT2CPT1BCYP2C9 | |
| SCHEMBL2002807 | 0.84 | RORC (0.60) | CPT1ARORCCPT2CPT1BCYP2C9 | |
| SCHEMBL2001670 | 0.83 | RORC (0.58) | CPT1ARORCHTR6CYP2C9 | |
| SCHEMBL2000702 | 0.83 | CPT1A (0.61) | CPT1ARORCCPT2CPT1B | |
| SCHEMBL2001969 | 0.82 | CPT1A (0.47) | CPT1ARORCCPT2CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-7960377-B2 | Substituted pyridoxazines | CARA THERAPEUTICS, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | US | disclosed |
| WO-2009120660-A2 | SUBSTITUTED PYRIDOXAZINES | CARA THERAPEUTICS, INC. (US) | 2009-10-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247502-A1 | SUBSTITUTED PYRIDOXAZINES | CNR1, CNR2, TRPV1 | CPT1A 3067/4885RORC 122/4885CPT2 4070/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.